The role of hypoxia in inflammatory disease (Review)

International Journal of Molecular Medicine

Volumn 35, Issue 4, 2015, Pages 859-869

  Biddlestone, John ^a,b   Bandarra, Daniel ^a   Rocha, Sonia ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b HEALTHCARE IMPROVEMENT SCOTLAND   (United Kingdom)

Author keywords

Colorectal cancer; Hypoxia; Inflammation; Inflammatory bowel disease; Rheumatoid arthritis

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXYGEN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR;

COLORECTAL CANCER; GENE TARGETING; HUMAN; HYPOXIA; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANIMAL; ANOXIA; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM;

ANIMALS; ANOXIA; ARTHRITIS, RHEUMATOID; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; NF-KAPPA B; OXYGEN; SIGNAL TRANSDUCTION;

EID: 84923673640     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2079     Document Type: Review

References (158)

1. Semenza GL: Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda) 24: 97-106, 2009.
2. Semenza GL: HIF-1 and human disease: One highly involved factor. Genes Dev 14: 1983-1991, 2000.
3. Perkins ND: The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer 12: 121-132, 2012.
4. Thornton RD, Lane P, Borghaei RC, Pease EA, Caro J and Mochan E: Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J 350: 307-312, 2000.
5. Taylor CT: Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol 586: 4055-4059, 2008.
6. Näthke I and Rocha S: Antagonistic crosstalk between APC and HIF-1α. Cell Cycle 10: 1545-1547, 2011.
7. Semenza GL and Wang GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454, 1992.
8. Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
9. Carroll VA and Ashcroft M: Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: Implications for targeting the HIF pathway. Cancer Res 66: 6264-6270, 2006.
10. Zhou J, Schmid T, Schnitzer S and Brüne B: Tumor hypoxia and cancer progression. Cancer Lett 237: 10-21, 2006.
11. Patel SA and Simon MC: Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ 15: 628-634, 2008.
12. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A and Poellinger L: Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414: 550-554, 2001.
13. Yamashita T, Ohneda O, Nagano M, et al: Abnormal heart development and lung remodeling in mice lacking the hypoxia-inducible factor-related basic helix-loop-helix PAS protein NEPAS. Mol Cell Biol 28: 1285-1297, 2008.
14. Zhang P, Yao Q, Lu L, Li Y, Chen PJ and Duan C: Hypoxia-inducible factor 3 is an oxygen-dependent transcription activator and regulates a distinct transcriptional response to hypoxia. Cell Rep 6: 1110-1121, 2014.
15. Bárdos JI and Ashcroft M: Negative and positive regulation of HIF-1: A complex network. Biochim Biophys Acta 1755: 107-120, 2005.
16. Rocha S: Gene regulation under low oxygen: Holding your breath for transcription. Trends Biochem Sci 32: 389-397, 2007.
17. Qin C, Wilson C, Blancher C, Taylor M, Safe S and Harris AL: Association of ARNT splice variants with estrogen receptor-negative breast cancer, poor induction of vascular endothelial growth factor under hypoxia, and poor prognosis. Clin Cancer Res 7: 818-823, 2001.
18. Kaelin WG Jr and Ratcliffe PJ: Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402, 2008.
19. Haase VH: Renal cancer: Oxygen meets metabolism. Exp Cell Res 318: 1057-1067, 2012.
20. Berra E, Benizri E, Ginouvès A, Volmat V, Roux D and Pouysségur J: HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22: 4082-4090, 2003.
21. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ and Gleadle JM: Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279: 38458-38465, 2004.
22. Epstein AC, Gleadle JM, McNeill LA, et al: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54, 2001.
23. Fandrey J, Gorr TA and Gassmann M: Regulating cellular oxygen sensing by hydroxylation. Cardiovasc Res 71: 642-651, 2006.
24. Bruegge K, Jelkmann W and Metzen E: Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr Med Chem 14: 1853-1862, 2007.
25. Frede S, Stockmann C, Freitag P and Fandrey J: Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-kappaB. Biochem J 396: 517-527, 2006.
26. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS and Kaelin WG Jr: HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292: 464-468, 2001.
27. Jaakkola P, Mole DR, Tian YM, et al: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
28. Yu F, White SB, Zhao Q and Lee FS: HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 98: 9630-9635, 2001.
29. Durán RV, MacKenzie ED, Boulahbel H, Frezza C, Heiserich L, Tardito S, Bussolati O, Rocha S, Hall MN and Gottlieb E: HIF-independent role of prolyl hydroxylases in the cellular response to amino acids. Oncogene 32: 4549-4556, 2013.
30. Moser SC, Bensaddek D, Ortmann B, Maure JF, Mudie S, Blow JJ, Lamond AI, Swedlow JR and Rocha S: PHD1 links cell-cycle progression to oxygen sensing through hydroxylation of the centrosomal protein Cep192. Dev Cell 26: 381-392, 2013.
31. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A and Semenza GL: Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145: 732-744, 2011.
32. Xie L, Pi X, Mishra A, Fong G, Peng J and Patterson C: PHD3-dependent hydroxylation of HCLK2 promotes the DNA damage response. J Clin Invest 122: 2827-2836, 2012.
33. Pugh CW, Tan CC, Jones RW and Ratcliffe PJ: Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene. Proc Natl Acad Sci USA 88: 10553-10557, 1991.
34. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P and Giallongo A: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271: 32529-32537, 1996.
35. Schödel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ and Mole DR: High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117: e207-e217, 2011.
36. Semenza GL: Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 19: 12-16, 2009.
37. Han YH, Xia L, Song LP, Zheng Y, Chen WL, Zhang L, Huang Y, Chen GQ and Wang LS: Comparative proteomic analysis of hypoxia-treated and untreated human leukemic U937 cells. Proteomics 6: 3262-3274, 2006.
38. Djidja MC, Chang J, Hadjiprocopis A, et al: Identification of hypoxia-regulated proteins using MALDI-mass spectrometry imaging combined with quantitative proteomics. J Proteome Res 13: 2297-2313, 2014.
39. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U and Bondesson M: Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9: 617-628, 2005.
40. Gordan JD, Bertout JA, Hu CJ, Diehl JA and Simon MC: HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11: 335-347, 2007.
41. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV and Neckers LM: Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392: 405-408, 1998.
42. Perkins ND: Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8: 49-62, 2007.
43. No authors listed: Celebrating 25 years of NF-κB. Nat Immunol 12: 681, 2011.
44. Campbell KJ and Perkins ND: Regulation of NF-kappaB function. Biochem Soc Symp 73: 165-180, 2006.
45. Wong D, Teixeira A, Oikonomopoulos S, et al: Extensive characterization of NF-κB binding uncovers non-canonical motifs and advances the interpretation of genetic functional traits. Genome Biol 12: R70, 2011.
46. Gilmore TD: The Rel/NF-kappaB signal transduction pathway: Introduction. Oncogene 18: 6842-6844, 1999.
47. Chen F, Castranova V, Shi X and Demers LM: New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45: 7-17, 1999.
48. Bandarra DR and Rocha S: A tale of two transcription factors: NF-κB and HIF crosstalk. OA Mol Cell Biol 1: 6, 2013.
49. Gilmore TD: Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene 25: 6680-6684, 2006.
50. Perkins ND and Gilmore TD: Good cop, bad cop: The different faces of NF-kappaB. Cell Death Differ 13: 759-772, 2006.
51. Aggarwal BB, Takada Y, Shishodia S, Gutierrez AM, Oommen OV, Ichikawa H, Baba Y and Kumar A: Nuclear transcription factor NF-kappa B: Role in biology and medicine. Indian J Exp Biol 42: 341-353, 2004.
52. Hackett PH and Roach RC: High-altitude illness. N Engl J Med 345: 107-114, 2001.
53. Hartmann G, Tschöp M, Fischer R, Bidlingmaier C, Riepl R, Tschöp K, Hautmann H, Endres S and Toepfer M: High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine 12: 246-252, 2000.
54. Kim HL, Cho YS, Choi H, Chun YS, Lee ZH and Park JW: Hypoxia-inducible factor 1alpha is deregulated by the serum of rats with adjuvant-induced arthritis. Biochem Biophys Res Commun 378: 123-128, 2009.
55. Boyd HK, Lappin TR and Bell AL: Evidence for impaired erythropoietin response to anaemia in rheumatoid disease. Br J Rheumatol 30: 255-259, 1991.
56. Grenz A, Clambey E and Eltzschig HK: Hypoxia signaling during intestinal ischemia and inflammation. Curr Opin Crit Care 18: 178-185, 2012.
57. Eltzschig HK, Sitkovsky MV and Robson SC: Purinergic signaling during inflammation. N Engl J Med 367: 2322-2333, 2012.
58. Bandarra D, Biddlestone J, Mudie S, Muller HA and Rocha S: Hypoxia activates IKK-NF-κB and the immune response in Drosophila melanogaster. Biosci Rep 34: 34, 2014.
59. Bandarra D, Biddlestone J, Mudie S, Muller HA and Rocha S: HIF-1α restricts NF-κB dependent gene expression to control innate immunity signals. Dis Model Mech: Dec 15, 2014 (Epub ahead of print).
60. van Uden P, Kenneth NS, Webster R, Müller HA, Mudie S and Rocha S: Evolutionary conserved regulation of HIF-1β by NF-κB. PLoS Genet 7: e1001285, 2011.
61. van Uden P, Kenneth NS and Rocha S: Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 412: 477-484, 2008.
62. Xue X, Ramakrishnan S, Anderson E, Taylor M, Zimmermann EM, Spence JR, Huang S, Greenson JK and Shah YM: Endothelial PAS domain protein 1 activates the inflammatory response in the intestinal epithelium to promote colitis in mice. Gastroenterology 145: 831-841, 2013.
63. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP and Haase VH: Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 114: 1098-1106, 2004.
64. Sewell KL and Trentham DE: Pathogenesis of rheumatoid arthritis. Lancet 341: 283-286, 1993.
65. Al-Shukaili AK and Al-Jabri AA: Rheumatoid arthritis, cytokines and hypoxia. What is the link. Saudi Med J 27: 1642-1649, 2006.
66. Gaber T, Dziurla R, Tripmacher R, Burmester GR and Buttgereit F: Hypoxia inducible factor (HIF) in rheumatology: Low O2! See what HIF can do. Ann Rheum Dis 64: 971-980, 2005.
67. Hueber W, Kidd BA, Tomooka BH, et al: Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 52: 2645-2655, 2005.
68. van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, Baeten DL, Dijkmans BA, Tak PP and Verweij CL: Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 12: R11, 2010.
69. van Wietmarschen HA, Dai W, van der Kooij AJ, et al: Characterization of rheumatoid arthritis subtypes using symptom profiles, clinical chemistry and metabolomics measurements. PLoS One 7: e44331, 2012.
70. Sweeney SE and Firestein GS: Signal transduction in rheumatoid arthritis. Curr Opin Rheumatol 16: 231-237, 2004.
71. Morel J and Berenbaum F: Signal transduction pathways: new targets for treating rheumatoid arthritis. Joint Bone Spine 71: 503-510, 2004.
72. Firestein GS and Manning AM: Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 42: 609-621, 1999.
73. Benito MJ, Murphy E, Murphy EP, van den Berg WB, FitzGerald O and Bresnihan B: Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum 50: 1781-1787, 2004.
74. Handel ML, McMorrow LB and Gravallese EM: Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 38: 1762-1770, 1995.
75. Müller-Ladner U, Pap T, Gay RE, Neidhart M and Gay S: Mechanisms of disease: The molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 1: 102-110, 2005.
76. Simmonds RE and Foxwell BM: Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 47: 584-590, 2008.
77. Westra J, Molema G and Kallenberg CG: Hypoxia-inducible factor-1 as regulator of angiogenesis in rheumatoid arthritis - therapeutic implications. Curr Med Chem 17: 254-263, 2010.
78. Ryu JH, Chae CS, Kwak JS, et al: Hypoxia-inducible factor-2α is an essential catabolic regulator of inflammatory rheumatoid arthritis. PLoS Biol 12: e1001881, 2014.
79. Hu F, Shi L, Mu R, et al: Hypoxia-inducible factor-1α and interleukin 33 form a regulatory circuit to perpetuate the inflammation in rheumatoid arthritis. PLoS One 8: e72650, 2013.
80. Brouwer E, Gouw AS, Posthumus MD, van Leeuwen MA, Boerboom AL, Bijzet J, Bos R, Limburg PC, Kallenberg CG and Westra J: Hypoxia inducible factor-1-alpha (HIF-1alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis. Clin Exp Rheumatol 27: 945-951, 2009.
81. Muz B, Khan MN, Kiriakidis S and Paleolog EM: Hypoxia. The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis. Arthritis Res Ther 11: 201, 2009.
82. Moniz S, Biddlestone J and Rocha S: Grow2: The HIF system, energy homeostasis and the cell cycle. Histol Histopathol 29: 589-600, 2014.
83. Kenneth NS and Rocha S: Regulation of gene expression by hypoxia. Biochem J 414: 19-29, 2008.
84. Poonam P: The biology of oral tolerance and issues related to oral vaccine design. Curr Pharm Des 13: 2001-2007, 2007.
85. Podolsky DK: Inflammatory bowel disease. N Engl J Med 347: 417-429, 2002.
86. Cummins EP, Doherty GA and Taylor CT: Hydroxylases as therapeutic targets in inflammatory bowel disease. Lab Invest 93: 378-383, 2013.
87. Abraham C and Cho JH: Inflammatory bowel disease. N Engl J Med 361: 2066-2078, 2009.
88. Giatromanolaki A, Sivridis E, Maltezos E, Papazoglou D, Simopoulos C, Gatter KC, Harris AL and Koukourakis MI: Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol 56: 209-213, 2003.
89. Danese S, Dejana E and Fiocchi C: Immune regulation by microvascular endothelial cells: Directing innate and adaptive immunity, coagulation, and inflammation. J Immunol 178: 6017-6022, 2007.
90. Werth N, Beerlage C, Rosenberger C, et al: Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogens. PLoS One 5: e11576, 2010.
91. Cummins EP, Seeballuck F, Keely SJ, Mangan NE, Callanan JJ, Fallon PG and Taylor CT: The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 134: 156-165, 2008.
92. Tambuwala MM, Cummins EP, Lenihan CR, et al: Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 139: 2093-2101, 2010.
93. Louis NA, Hamilton KE, Kong T and Colgan SP: HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils. FASEB J 19: 950-959, 2005.
94. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF and Colgan SP: Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 110: 993-1002, 2002.
95. Kong T, Westerman KA, Faigle M, Eltzschig HK and Colgan SP: HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J 20: 2242-2250, 2006.
96. Louis NA, Hamilton KE, Canny G, Shekels LL, Ho SB and Colgan SP: Selective induction of mucin-3 by hypoxia in intestinal epithelia. J Cell Biochem 99: 1616-1627, 2006.
97. Furuta GT, Turner JR, Taylor CT, Hershberg RM, Comerford K, Narravula S, Podolsky DK and Colgan SP: Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med 193: 1027-1034, 2001.
98. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC and Colgan SP: Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: 3387-3394, 2002.
99. Neurath MF, Pettersson S, Meyer zum Büschenfelde KH and Strober W: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 2: 998-1004, 1996.
100. Holtmann MH and Neurath MF: Differential TNF-signaling in chronic inflammatory disorders. Curr Mol Med 4: 439-444, 2004.
101. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF and Karin M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285-296, 2004.
102. Pasparakis M: IKK/NF-kappaB signaling in intestinal epithelial cells controls immune homeostasis in the gut. Mucosal Immunol 1 (Suppl 1): S54-S57, 2008.
103. Zaph C, Troy AE, Taylor BC, et al: Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature 446: 552-556, 2007.
104. Hauser CJ, Locke RR, Kao HW, Patterson J and Zipser RD: Visceral surface oxygen tension in experimental colitis in the rabbit. J Lab Clin Med 112: 68-71, 1988.
105. Shah YM, Ito S, Morimura K, et al: Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology 134: 2036-2048, 2048 e2031-2033, 2008.
106. Hara H and Saito T: CARD9 versus CARMA1 in innate and adaptive immunity. Trends Immunol 30: 234-242, 2009.
107. Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X, Zhang L, Kim WY, Olumi AF and Kaelin WG Jr: pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 28: 15-27, 2007.
108. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG and Karin M: NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453: 807-811, 2008.
109. Bracken CP, Whitelaw ML and Peet DJ: Activity of hypoxia-inducible factor 2alpha is regulated by association with the NF-kappaB essential modulator. J Biol Chem 280: 14240-14251, 2005.
110. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, Paquette RL and Baltimore D: Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205: 585-594, 2008.
111. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
112. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
113. Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P and Jain RK: Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha-> hypoxia response element-> VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res 60: 6248-6252, 2000.
114. Shay JE, Imtiyaz HZ, Sivanand S, et al: Inhibition of hypoxia-inducible factors limits tumor progression in a mouse model of colorectal cancer. Carcinogenesis 35: 1067-1077, 2014.
115. Rawluszko-Wieczorek AA, Horbacka K, Krokowicz P, Misztal M and Jagodzinski PP: Prognostic potential of DNA methylation and transcript levels of HIF1A and EPAS1 in colorectal cancer. Mol Cancer Res: 12: 1112-1127, 2014.
116. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC and Huang LE: HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 23: 1949-1956, 2004.
117. Sánchez-Puig N, Veprintsev DB and Fersht AR: Binding of natively unfolded HIF-1alpha ODD domain to p53. Mol Cell 17: 11-21, 2005.
118. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL and Bedi A: Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14: 34-44, 2000.
119. Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY and Dewhirst MW: Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8: 99-110, 2005.
120. Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth D, Keith B, Brown EJ, Nathanson KL and Simon MC: HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci USA 106: 14391-14396, 2009.
121. Volm M and Koomägi R: Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 20: 1527-1533, 2000.
122. Evans AJ, Russell RC, Roche O, et al: VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 27: 157-169, 2007.
123. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC and Wu KJ: Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10: 295-305, 2008.
124. Gort EH, van Haaften G, Verlaan I, et al: The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha. Oncogene 27: 1501-1510, 2008.
125. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
126. Sahlgren C, Gustafsson MV, Jin S, Poellinger L and Lendahl U: Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 105: 6392-6397, 2008.
127. Lakatos PL and Lakatos L: Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. World J Gastroenterol 14: 3937-3947, 2008.
128. Munkholm P: Review article: The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18 (Suppl 2): 1-5, 2003.
129. Fernández-Majada V, Aguilera C, Villanueva A, et al: Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proc Natl Acad Sci USA 104: 276-281, 2007.
130. Seril DN, Liao J, Yang GY and Yang CS: Oxidative stress and ulcerative colitis-associated carcinogenesis: Studies in humans and animal models. Carcinogenesis 24: 353-362, 2003.
131. Sangha S, Yao M and Wolfe MM: Non-steroidal anti-inflammatory drugs and colorectal cancer prevention. Postgrad Med J 81: 223-227, 2005.
132. Hoffmeister M, Chang-Claude J and Brenner H: Do older adults using NSAIDs have a reduced risk of colorectal cancer. Drugs Aging 23: 513-523, 2006.
133. Becker C, Fantini MC, Schramm C, et al: TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21: 491-501, 2004.
134. Greten FR, Arkan MC, Bollrath J, et al: NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130: 918-931, 2007.
135. Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002.
136. Richmond A: Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2: 664-674, 2002.
137. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
138. Schulze-Bergkamen H and Krammer PH: Apoptosis in cancer-implications for therapy. Semin Oncol 31: 90-119, 2004.
139. Kucharczak J, Simmons MJ, Fan Y and Gélinas C: To be, or not to be: NF-kappaB is the answer - role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 22: 8961-8982, 2003.
140. Luo JL, Kamata H and Karin M: IKK/NF-kappaB signaling: Balancing life and death - a new approach to cancer therapy. J Clin Invest 115: 2625-2632, 2005.
141. Cornejo MG, Boggon TJ and Mercher T: JAK3: A two-faced player in hematological disorders. Int J Biochem Cell Biol 41: 2376-2379, 2009.
142. Lin Q, Lai R, Chirieac LR, et al: Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: Inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 167: 969-980, 2005.
143. Tsareva SA, Moriggl R, Corvinus FM, Wiederanders B, Schütz A, Kovacic B and Friedrich K: Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia 9: 279-291, 2007.
144. Guttridge DC, Albanese C, Reuther JY, Pestell RG and Baldwin AS Jr: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19: 5785-5799, 1999.
145. Chen C, Edelstein LC and Gélinas C: The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20: 2687-2695, 2000.
146. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107: 241-246, 2001.
147. Choo MK, Sakurai H, Kim DH and Saiki I: A ginseng saponin metabolite suppresses tumor necrosis factor-α-promoted metastasis by suppressing nuclear factor-κB signaling in murine colon cancer cells. Oncol Rep 19: 595-600, 2008.
148. Thomasova D, Mulay SR, Bruns H and Anders HJ: p53-independent roles of MDM2 in NF-κB signaling: Implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia 14: 1097-1101, 2012.
149. Puvvada SD, Funkhouser WK, Greene K, Deal A, Chu H, Baldwin AS, Tepper JE and O'Neil BH: NF-κB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology 78: 181-188, 2010.
150. Kwon HC, Kim SH, Oh SY, et al: Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer. Cancer Sci 101: 1557-1561, 2010.
151. Wu Y and Zhou BP: TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 102: 639-644, 2010.
152. Schwitalla S, Ziegler PK, Horst D, et al: Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 23: 93-106, 2013.
153. Terzic J, Grivennikov S, Karin E and Karin M: Inflammation and colon cancer. Gastroenterology 138: 2101-2114 e2105, 2010.
154. Newton IP, Kenneth NS, Appleton PL, Näthke I and Rocha S: Adenomatous polyposis coli and hypoxia-inducible factor-1{alpha} have an antagonistic connection. Mol Biol Cell 21: 3630-3638, 2010.
155. Bienz M and Clevers H: Linking colorectal cancer to Wnt signaling. Cell 103: 311-320, 2000.
156. McCartney BM and Näthke IS: Cell regulation by the Apc protein Apc as master regulator of epithelia. Curr Opin Cell Biol 20: 186-193, 2008.
157. Wen D, Zhang N, Shan B and Wang S: Helicobacter pylori infection may be implicated in the topography and geographic variation of upper gastrointestinal cancers in the Taihang Mountain high-risk region in northern China. Helicobacter 15: 416-421, 2010.
158. Krüger B, Krick S, Dhillon N, et al: Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci USA 106: 3390-3395, 2009.